Literature DB >> 1812012

Comparison of the effects of benzodiazepine and beta-carboline inverse agonists on body temperature in mice.

H C Jackson1, D J Nutt.   

Abstract

The effect of benzodiazepine and beta-carboline inverse agonists on body temperature in mice was investigated using doses shown to be pro-convulsant in other studies. The benzodiazepine partial inverse agonists Ro 15-3505 (0.1-30 mg/kg i.p.), Ro 15-4513 (0.1-10 mg/kg i.p.) and the fuller benzodiazepine inverse agonist Ro 19-4603 (0.03-0.3 mg/kg i.p.) had no effect on rectal temperature. Ro 19-4603 (1 mg/kg i.p.) produced a small hypothermic response. In contrast, the beta-carboline partial and full inverse agonists, FG 7142 (30, 60 mg/kg i.p.) and methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (3, 10 mg/kg i.p.), produced large decreases in body temperature. These differential effects of benzodiazepine and beta-carboline inverse agonists on body temperature may provide further evidence for the existence of benzodiazepine receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812012     DOI: 10.1016/0014-2999(91)90823-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Stress-induced changes in respiratory quotient, energy expenditure and locomotor activity in rats: effects of midazolam.

Authors:  I S McGregor; A M Lee; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

2.  Strain differences in sensitivity to the hypothermic effects of benzodiazepine receptor ligands in mice.

Authors:  H C Jackson; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Alprazolam-induced EEG spectral power changes in rhesus monkeys: a translational model for the evaluation of the behavioral effects of benzodiazepines.

Authors:  Lais F Berro; John S Overton; Jaren A Reeves-Darby; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2021-02-16       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.